Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan Prialt Clears FDA, Will Launch In Late January

This article was originally published in The Pink Sheet Daily

Executive Summary

Intrathecal therapy is indicated for "the management of severe chronic pain in patients…who are intolerant or refractory to other treatment." Elan will promote the non-opioid therapy with 40 to 50 sales reps targeting 3,000 doctors.
Advertisement

Related Content

Overly Aggressive Prialt Dose Data Are Not Surrogate Endpoints, FDA Says
Overly Aggressive Prialt Dose Data Are Not Surrogate Endpoints, FDA Says
Biogen Idec Shifting Tysabri Sales Force To Avonex Detail
Biogen Idec Shifting Tysabri Sales Force To Avonex Detail
DEA Developing Pain Drug Prescribing Policy
DEA Developing Pain Drug Prescribing Policy
Elan/Biogen Idec's Tysabri, Formerly Antegren, Approved For MS Based On One-Year Data
Elan Prialt NDA Amendment Puts Drug On Schedule For Early 2005 Launch
Elan Prialt NDA Amendment Puts Drug On Schedule For Early 2005 Launch

Topics

Advertisement
UsernamePublicRestriction

Register

PS058476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel